The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
HorningS.J., HoppeR.T., BreslinS.Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol.2002; 20(3): 630–637.
2.
BartlettN.L., RosenbergS.A., HoppeR.T.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol.1995; 15(5): 1080–1088.
3.
HorningS.J., RosenbergS.A., HoppeR.T.Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol.1996; 7(Suppl 4): S105–S108.
4.
HorningS.J., WilliamsJ., BartlettN.L.Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol.2000; 18(5): 972–980.
5.
ChisesiT., FedericoM., LevisA.ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol.2002; 13(Suppl 1): 102–106.
6.
AversaS.M., SalvagnoL., SorarùM.,Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol.2004; 112(3): 141–147.
7.
GobbiP.G., LevisA., ChisesiT.ABVD versus Modified Stanford V versus MOPPEBVCAD with optimal and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol.2005; 23: 9198–9207.
8.
AbuzetunJ.Y., LoberizaF., VoseJ.The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol.2008; 144: 531–537.
9.
SpinaM., GabarreJ., RossiG.Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood.2002; 100(6): 1984–1988.
10.
HohausS., Di FeboA., StortiS., TeofiliL., VosoM.T., LeoneG.Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. Haematologica.2004; 89(6): 751–752.
11.
HoskinP.J., LowryL., HorwichA.Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol.2009; 27(32): 5390–5396.
12.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Hodgkin Lymphoma. V.2.2010. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 6, 2010.
TrisselL.A.Handbook on Injectable Drugs. 15th ed.Bethesda, MD: ASHP; 2009: 1007.
15.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–745.
16.
TrisselL.A.Handbook on Injectable Drugs. 15th ed.Bethesda, MD: ASHP; 2009: 1573–1578.
17.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol.2006; 24: 2932–2947.
20.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2008. Multinational Association for Supportive Care in Cancer Web site. Accessed September 6, 2010.
21.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
22.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
23.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
24.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
25.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
26.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
LamM.S.A.The need for routine bleomycin test dosing in the 21st century. Ann Pharmacother.2005; 39(11): 1897–1902.
29.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
AronoffG.R., BennettW.M., BernsJ.S., BrierM.E., KasbekarN., MuellerB.A., PaskoD.A., SmoyerW.E.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
36.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
37.
KingPD., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
38.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
